News
Bristol Myers tops revenue expectations on strength of older drugs, shares fall
(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%.
Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.
Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...
Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...
Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback